Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib in Advanced ALK-Positive NSCLC
NCT07140016Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2025
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of gilteritinib in non-small cell lung cancer (NSCLC), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 53 months and 6 more. Started Sep 2025; status: recruiting.
02
Drugs
gilteritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07140016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140016.